U.S. Capital Wealth Advisors LLC Increases Stock Position in AstraZeneca PLC (NASDAQ:AZN)

U.S. Capital Wealth Advisors LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 25.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,933 shares of the company’s stock after purchasing an additional 1,008 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in AstraZeneca were worth $323,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Martin Investment Management LLC increased its holdings in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after buying an additional 7,615 shares during the last quarter. Nordea Investment Management AB purchased a new stake in AstraZeneca during the fourth quarter worth about $754,000. Diversify Wealth Management LLC increased its holdings in AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after buying an additional 153 shares during the last quarter. Ameritas Advisory Services LLC increased its holdings in AstraZeneca by 25.9% during the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after buying an additional 1,949 shares during the last quarter. Finally, Integrated Advisors Network LLC increased its holdings in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

AZN stock opened at $72.36 on Friday. The firm has a 50 day moving average of $67.27 and a 200-day moving average of $73.70. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The firm has a market capitalization of $224.39 billion, a P/E ratio of 34.62, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.